Journal of Gastroenterology

, Volume 41, Issue 6, pp 524–532

Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients

  • Ken Fukunaga
  • Yoshihiro Fukuda
  • Yoko Yokoyama
  • Kunio Ohnishi
  • Takeshi Kusaka
  • Tadashi Kosaka
  • Nobuyuki Hida
  • Yoshio Ohda
  • Hiroto Miwa
  • Takayuki Matsumoto



Leukocytapheresis (LCAP) is an effective adjunct for patients with active ulcerative colitis (UC). Because LCAP may have the potential to remove and modulate not only leukocytes but also platelets, we evaluated the correlation between activated platelets and the therapeutic response to LCAP.


Fourteen patients with severe UC received weekly LCAP for 5 consecutive weeks. Their average clinical activity index (CAI) and endoscopic index (EI) were 9.6 ± 3.4 and 10.9 ± 1.0, respectively. Their peripheral blood was sampled before and after every LCAP and stained with fluorescent antibodies to the activation-dependent surface antigens of platelets (CD63, CD62-P) prior to flow cytometry. Endoscopic evaluations were performed after the last LCAP.


Clinical remission (CAI < 4) was induced in 50% of the patients (7/14) after 5 weeks, and there were no significant differences observed in clinical background between the responder group (RG) and the nonresponder group (NG). In the RG, the populations of CD63+ (P < 0.03) and CD62-P+ (P < 0.05) platelets were significantly decreased after the first LCAP, and their reduction ratio decreased gradually with repeated LCAP. A significant improvement of the EI score, especially mucosal damage, was achieved in RG (P < 0.04) but not in NG.


These results indicate that the therapeutic responses to LCAP were reflected in modulations of population and/or platelet functions, especially after the first session. The decrease of such activated platelets immediately after the first LCAP may be an early marker for predicting the response in patients with severe UC.

Key words

ulcerative colitis platelets P-selectin leukocytapheresis inflammatory bowel disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sawada, K, Ohnishi, K, Fukui, S, Yamada, K, Yamamura, M, Tanida, N,  et al. 1995Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel diseaseJ Gastroenterol303229PubMedCrossRefGoogle Scholar
  2. 2.
    Sawada, K, Muto, T, Shimoyama, T, Satomi, M, Sawada, T, Nagawa, H,  et al. 2003Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis columnCurr Pharmaceutical Design930721CrossRefGoogle Scholar
  3. 3.
    Shibata, H, Kuriyama, T, Yamawaki, N 2003CellsorbaTher Apher Dial7447PubMedCrossRefGoogle Scholar
  4. 4.
    Danese S, Motte C, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004;938–45Google Scholar
  5. 5.
    Talstad, I, Rootwelt, K, Gjone, E 1973Thrombocytosis in ulcerative colitis and Crohn's diseaseScand J Gastroenterol81358PubMedGoogle Scholar
  6. 6.
    Harries, AD, Fitzsimons, E, Fifield, R, Dew, MJ, Rhoades, J 1983Platelet count: a simple measure of activity in Crohn's diseaseBr Med J2861476CrossRefGoogle Scholar
  7. 7.
    Larsen, E, Celi, A, Gilbert, GE, Furie, BC, Erban, JK, Bonfanti, R,  et al. 1989PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytesCell5930512PubMedCrossRefGoogle Scholar
  8. 8.
    Lichtiger, S, Present, DH, Kornbluth, A 1994Cyclosporine in severe ulcerative colitis refractory to steroid therapyN Engl J Med33018415PubMedCrossRefGoogle Scholar
  9. 9.
    Rachmilewitz, D 1989Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trialBMJ298826PubMedCrossRefGoogle Scholar
  10. 10.
    Fukunaga, K, Shimoyama, T, Yamaji, K, Yamane, S, Sueoka, A, Nosé, Y 1999In vitro comparison study of CD63 and CD62P expression after contacting leukocyte filtersArtif Organs2310813PubMedCrossRefGoogle Scholar
  11. 11.
    Podolsky, DK 2002Inflammatory bowel diseaseN Engl J Med34741729PubMedCrossRefGoogle Scholar
  12. 12.
    Kornbluth, A, Sachar, DB 1997Ulcerative colitis practice guideline in adults. American College of Gastroenterology, Practice Parameters CommitteeAm J Gastroenterol9220411PubMedGoogle Scholar
  13. 13.
    Noguchi, M, Hiwatashi, N, Hayakawa, T, Toyota, T 1998Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppressionTher Apher210914PubMedGoogle Scholar
  14. 14.
    Hanai, H, Iida, T, Takeuchi, K, Watanabe, F, Maruyama, Y, Kikuyama, M,  et al. 2005Decrease of reactive-oxygen–producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitisWorld J Gastroenterol11308590PubMedGoogle Scholar
  15. 15.
    Morowitz, DA, Allen, LW, Kirsner, JB 1968Thrombocytosis in chronic inflammatory bowel diseaseAnn Intern Med68101321PubMedGoogle Scholar
  16. 16.
    Gerdsen, F, Weber, M, Langer, F, Eifrig, B, Lindhoff-Last, E 2005Platelet activation markers in patients with venous thromboembolism without predisposing factorsPathophysiol Haemost Thromb3415PubMedCrossRefGoogle Scholar
  17. 17.
    Tan, KT, Tayebjee, MH, Macfadyen, RJ, Lip, GYH, Blann, AD 2005Elevated platelet microparticles in stable coronary artery disease are unrelated to disease severity or to indices of inflammationPlatelets1636871PubMedCrossRefGoogle Scholar
  18. 18.
    Rembacken, BJ, Newbould, HE, Richards, SJ 1998Granulocyte apheresis in inflammatory bowel disease: possible mechanisms of effectTher Apher2936PubMedGoogle Scholar
  19. 19.
    Hiraishi, K, Takeda, Y, Shiobara, N 2003Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresisTherap Apher Dial733440CrossRefGoogle Scholar
  20. 20.
    D'Arrigo, C, Candal-Couto, JJ, Greer, M,  et al. 1993Human neutrophil Fc receptor-mediated adhesion under flow: a hollow fiber model of intravascular arrestClin Exp Immunol1001739CrossRefGoogle Scholar
  21. 21.
    Hiramatsu, Y, Homma, S, Sato, Y, Sato, S, Matsuzaki, K, Shigeta, O,  et al. 2005Nafamostat preserves neutrophils deformability and reduces microaggregate formation during stimulated extracorporeal circulationAnn Thorac Surg79132632PubMedCrossRefGoogle Scholar
  22. 22.
    Yamaji, K, Yang, K, Tsuda, H, Hashimoto, H 2002Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteersTher Apher640212PubMedCrossRefGoogle Scholar
  23. 23.
    Matts, SGF 1961The value of rectal biopsy in the diagnosis of ulcerative colitisQ J Med120393407Google Scholar
  24. 24.
    Fukunaga, K, Fukuda, Y, Sawada, K, Hori, K, Matoba, Y, Sagayama, K,  et al. 2003Poorly controlled ulcerative colitis treated by colectomy during remission induced by extracorporeal leukocyte removal therapyJ Gastroenterol386849PubMedCrossRefGoogle Scholar
  25. 25.
    Raddatz, D, Middel, P, Bockemuhl, M, Benohr, P, Wismann, C, Schworer, H,  et al. 2004Glucocorticoid receptor expression in inflammatory bowel disease: evidence for a mucosal down-regulation in steroid-unresponsive ulcerative colitisAlim Pharm Ther194761CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 2006

Authors and Affiliations

  • Ken Fukunaga
    • 1
  • Yoshihiro Fukuda
    • 1
  • Yoko Yokoyama
    • 1
  • Kunio Ohnishi
    • 1
  • Takeshi Kusaka
    • 1
  • Tadashi Kosaka
    • 1
  • Nobuyuki Hida
    • 1
  • Yoshio Ohda
    • 1
  • Hiroto Miwa
    • 2
  • Takayuki Matsumoto
    • 1
  1. 1.Division of Lower Gastroenterology, Department of Internal MedicineHyogo College of MedicineNishinomiyaJapan
  2. 2.Division of Upper Gastroenterology, Department of Internal MedicineHyogo College of MedicineNishinomiyaJapan

Personalised recommendations